Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Harrow Health ( (HROW) ) just unveiled an announcement.
Harrow reported that 2025 was a “defining year,” with record fourth-quarter revenue of $89.1 million, up 33% year on year, and full-year revenue rising 36% to $272.3 million as of December 31, 2025. Despite posting a net loss of $5.1 million for 2025, the company generated $43.9 million in operating cash flow versus a cash outflow in 2024, maintained gross margins at 75%, and ended the year with $72.9 million in cash and equivalents.
Management highlighted strengthening demand for key ophthalmic products VEVYE, IHEEZO and TRIESENCE, and said 2025 operating leverage and cash generation support Harrow’s evolution toward a larger-scale commercial player. For 2026, the company issued revenue guidance of $350 million to $365 million and Adjusted EBITDA of $80 million to $100 million, while pledging more transparent, conservative guidance and outlining plans to scale sales teams, expand IHEEZO’s use, integrate the Melt Pharmaceuticals acquisition and prepare late-stage assets for launches beyond 2027.
The most recent analyst rating on (HROW) stock is a Buy with a $74.00 price target. To see the full list of analyst forecasts on Harrow Health stock, see the HROW Stock Forecast page.
Spark’s Take on HROW Stock
According to Spark, TipRanks’ AI Analyst, HROW is a Neutral.
The score is held back primarily by weaker financial quality (high leverage and poor/declining cash flow despite strong gross margins and revenue growth). Earnings-call commentary is a key offset, pointing to strong recent growth, operating leverage, and reiterated revenue guidance, while technicals are mixed and valuation is challenged by a negative P/E and no dividend support.
To see Spark’s full report on HROW stock, click here.
More about Harrow Health
Harrow Inc. is a Nashville-based pharmaceutical company specializing in ophthalmic disease management solutions in North America. It offers a broad portfolio of products for conditions affecting the front and back of the eye, including dry eye disease, age-related macular degeneration, cataracts, refractive errors, glaucoma, ocular surface disorders, and retina diseases, with a focus on safe, accessible and affordable medications that improve outcomes.
The company has been expanding its commercial footprint through branded products such as VEVYE, IHEEZO and TRIESENCE, which are in relatively early launch phases but are gaining traction. Harrow aims to transition from an early-stage growth business to a cash-generating commercial platform, leveraging both its existing portfolio and future late-stage ophthalmic assets under development.
Average Trading Volume: 565,833
Technical Sentiment Signal: Buy
Current Market Cap: $2.01B
Learn more about HROW stock on TipRanks’ Stock Analysis page.